Agilent Technologies and Samsung Medical Center to Collaborate
News Jul 22, 2012
Clinical assays are investigative procedures that measure how drugs or biochemical substances react or respond in human samples.
"Based on our memoradum of understanding, projects such as the discovery and validation of protein biomarkers for applications in clinical trials, the development of methodology for applications involving hormones and vitamins, and assay development for a tumor marker for certain cancers and diseases will be undertaken at Samsung Medical Center in cooperation with Agilent," said professor Sung-Hwa Hong, executive vice president, Research & Development, Samsung Medical Center.
"For the detailed and rigorous tests required for these research projects, Agilent will provide our top-end bio-analytical instruments, on-site and remote application, and technical support, as well as our research experts to work closely with professor Hong's team," said Rod Minett, general manager of Agilent's life sciences business in South Korea and the South Asia Pacific region. "We look forward to close collaboration with Samsung Medical Center so as to accelerate the advancement of science and medical developments, and ultimately to improve the quality of life for mankind."
The Samsung Medical Center will use the following instruments from Agilent:
• Agilent 6530 Accurate-Mass Q-TOF LC/MS (liquid chromatography/mass spectrometry), which is able to profile, identify, characterize and quantify compounds accurately and quickly."In addition, researchers from both Samsung Medical Center and Agilent plan to work on joint research projects that evaluate novel and powerful analytical technologies for future uses in clinical environments," said professor Rudolf Grimm, Agilent's collaborations manager for South Korea and the South Asia Pacific region.
• Agilent 6430 Triple Quadrupole LC/MS System, which is well-suited for environments where parts-per-trillion sensitivity is required.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Eating Activates Calorie-Burning FatNews
The importance of the human brown adipose tissue (BAT) has become clearer during the past ten years. Coldness is one of the most effective activators of the BAT metabolic function but, in rodents, eating has also been shown to activate BAT. The debate on whether eating has the same effect on humans has lasted for decades. Now, the researchers at Turku PET Centre have proven that having a meal increases oxygen consumption in human BAT to the same extent as coldness.READ MORE